Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 57 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: bimatoprost solution Clear all

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost, Timolol 0.5%, Placebo Ocular Insert, Placebo Eye Drops; Drug · Device
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 10
States / cities: Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 7 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: 0.1% brimonidine tartrate ophthalmic solution, 0.01% bimatoprost ophthalmic solution, 0.2% hypromellose lubricant eye drops, latanoprost 0.005% ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Deerfield Beach, Florida

Conditions: Alopecia Areata
Interventions: Latanoprost (Xalatan), Bimatoprost (Lumigan), Topical application of latanoprost solution to eyelid; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: bimatoprost ophthalmic solution 0.01%, travoprost ophthalmic solution 0.004%, latanoprost ophthalmic solution 0.005%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rogers, Arkansas

Conditions: Glaucoma, Ocular Hypertension
Interventions: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Eyelash Hypotrichosis
Interventions: bimatoprost ophthalmic solution 0.005%, bimatoprost ophthalmic solution 0.015%, bimatoprost ophthalmic solution 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 30 Years to 55 Years · Female only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Eyelash Hypotrichosis, Alopecia Areata
Interventions: bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Madarosis, Hypotrichosis
Interventions: Bimatoprost eyelash gel; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glaucoma
Interventions: Prostaglandin Analogue -Containing IOP-Lowering Therapy, Beta Blocker, Brillouin Microscopy; Drug · Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2, bimatoprost 6 µg generation 2, bimatoprost 15 µg generation 1, bimatoprost 10 µg generation 1, bimatoprost 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 36
States / cities: Artesia, California • La Jolla, California • Los Angeles, California + 31 more

Conditions: Ocular Hypertension, Glaucoma
Interventions: bimatoprost 0.03% eye drops, latanoprost 0.005% eye drops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Artesia, California

Conditions: Migraine Disorders, Headache Disorders
Interventions: Bimatoprost Topical Solution, Control; Drug
Lead sponsor: Manistee Partners; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Cincinnati, Ohio • Warwick, Rhode Island

Conditions: Alopecia, Baldness
Interventions: bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C, bimatoprost vehicle solution, minoxidil 2% solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 59 Years · Female only
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Glaucoma, Ocular Hypertension
Interventions: Fixed-Combination Bimatoprost/Brimonidine, Bimatoprost Ophthalmic Solution 0.01%, Vehicle Ophthalmic Solution, Brimonidine Tartrate Ophthalmic Solution 0.2%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 40 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Alopecia, Alopecia, Androgenetic, Baldness
Interventions: Bimatoprost; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Austin, Texas • College Station, Texas • Lynchburg, Virginia

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.03% Formulation B Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Cataract, Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL; Drug · Device
Lead sponsor: SpyGlass Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.01% Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution, Bimatoprost Vehicle Ophthalmic Solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 20 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Androgenetic Alopecia
Interventions: Bimatoprost 1% Formulation A, Bimatoprost 1% Formulation B; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Nail Growth Cessation, Intraocular Pressure
Interventions: Bimatoprost 0.01%, Placebo: saline; Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Glenview, Illinois

Conditions: Eyelashes
Interventions: Bimatoprost 0.03% sterile solution, vehicle sterile solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: bimatoprost 0.03% eye drops, travoprost 0.004% eye drops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Dose-Ranging Study of the Bimatoprost Ocular Insert

A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension

Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence

Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

Study of Bimatoprost Gel on Eyelash Growth

Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Topical Bimatoprost in the Treatment of Migraine

Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss

A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure

Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%